Inhalable Antimicrobial Particles for Tuberculosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis (TB) treatments face challenges such as drug intolerance, toxicity, and the emergence of multi-drug resistant strains due to inadequate delivery strategies, with existing formulations like PLGA microspheres being toxic and ineffective against dormant bacteria.
Innovation Solution
Development of drug delivery particles comprising an anionic polymer matrix and cationic polymer bound by electrostatic interactions, loaded with biologically active agents like rifampicin, which are administered as a dry powder for inhalation to enhance local drug concentration and control release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard oral multi-drug cocktail is administered for 6 months, then cure rate is >95%, but treatment burden and toxicity increase leading to non-compliance and drug resistance
Solution Approach 1:
The patent segments the treatment by delivering drugs directly to the lung infection site via inhalable particles, separating the treatment location from systemic circulation. This localized delivery maintains high cure rates while reducing the burden of taking multiple oral drugs daily under direct observation.
Solution Approach 2:
The patent uses inhalable particles as an intermediary carrier system that delivers antimicrobial drugs directly to the lung. This mediator bypasses the need for oral administration and direct observation, reducing treatment burden while maintaining effectiveness.
2Duration of action of moving object
If PLGA microspheres are used for drug delivery, then sustained release is achieved, but toxicity and allergic reactions occur
Solution Approach 1:
The patent changes the material composition parameters from synthetic PLGA polymers to natural polymers (alginate, chitosan, gelatin) that are biodegradable and non-toxic. This parameter change maintains sustained release functionality while eliminating the toxicity and allergic reactions associated with PLGA microspheres.
Solution Approach 2:
The patent employs natural polymers that are biodegradable and disappear from the system after performing their function. These disposable-like carriers break down into harmless products, avoiding long-term toxicity issues while providing sustained drug release during the treatment period.
3Productivity
If conventional antibiotics are used, then replicating bacteria are killed, but dormant bacteria remain resistant and treatment must be extended
Solution Approach 1:
The patent formulates particles that can deliver multiple antimicrobial agents simultaneously, creating a multi-functional treatment approach. This combination therapy targets both replicating and dormant bacteria with different mechanisms of action, improving overall bacterial killing efficiency and reducing the need for extended treatment duration.
Solution Approach 2:
The patent uses composite particle formulations combining natural polymer matrices with various antimicrobial agents. This composite approach allows synergistic effects between different drugs, enhancing efficacy against both active and dormant bacteria while potentially shortening the overall treatment course.
4Reliability
If direct observation of therapy is implemented, then compliance is improved, but healthcare worker resources are consumed
Solution Approach 1:
The patent enables patients to self-administer the treatment through simple inhalation of the dry powder formulation at home. The particles are designed for easy inhalation without requiring healthcare worker presence, allowing patients to manage their own therapy while maintaining compliance through the convenience and simplicity of the delivery system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation improves the pharmacological and therapeutic properties of TB drugs, achieving sustained release and preferential localization to infected tissues, effectively targeting both replicating and dormant TB bacteria, thereby shortening treatment duration and reducing resistance.
Implementation Method 1
a cationic polymer; wherein the anionic polymer matrix and cationic polymer together form drug delivery particles bound by electrostatic interactions
Data Source
AI summary
The present invention relates in part to novel drug delivery particles comprising an anionic polymer matrix and a cationic polymer, wherein the anionic polymer matrix and cationic polymer together form drug delivery particles bound by electrostatic interactions and wherein the drug delivery particles comprise at least one biologically active agent. The invention also relates in part to a method of treating a mycobacterial infection using said drug delivery particles, and a method of making said drug delivery particles.